General Methods. 1 H NMR spectra were measured in CDCl 3 solution and referenced to TMS (0.00 ppm) using JEOL JNM-ECA 600 (600 MHz) spectrometers, unless otherwise noted. Peak multiplicities are used the following abbreviation: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. All reactions were performed under an air atmosphere unless otherwise noted, and tetrahydrofuran (THF) were purchased from Kanto Chemical Co., Inc., and other solvent was distilled. Unless otherwise noted, reagents were obtained from chemical sources and without further purification.
Recombinant expression and purification of anti-BGP scFv. E. coli SHuffle T7 Express lysY cells were transformed with pSQ(KTM219) 1 and cultured at 30 °C for 16 h in LBA medium (LB medium containing 100 μg/mL ampicillin) and 1.5% agar. A single colony was picked and grown at 30 °C in 4 mL of LBA medium until OD 600 of 0.9 was reached, from which 1.6 mL were used to inoculate 100 mL of LBA medium. The cells were cultured at 30 °C until an OD 600 of 0.6 was reached, when 0.4 mM isopropylthio-β-galactopyranoside was added. The solution was incubated for 16 h at 16 °C and centrifuged (8000 × g, 20 min, 4 °C). The pellet was resuspended in 10 mL of Talon wash buffer (50 mM phosphate, 0.3 M sodium chloride (NaCl), 5 mM imidazole, pH 7.4) and sonicated. After centrifugation (8000 × g, 20 min, 4°C), the supernatant was incubated with 0.2 mL of Talon metal affinity resin on a rotating wheel for 30 min at 25 °C. The beads were transferred to a Talon disposable gravity column, and washed three times with 8 mL Talon wash buffer. After adding 4 mL of Talon elution buffer (50 mM phosphate, 0.3 M NaCl, 0.5 M imidazole, pH 7.4) and incubation at 25 °C for 30 min, the eluent was collected. The eluent was subjected to an ultrafiltration device and equilibrated with PBS (10 mM phosphate, 137 mM NaCl, 2.7 mM potassium chloride, pH 7.4) and concentrated to 250 μL. The expression and purification of the protein were confirmed using a SDS-PAGE analysis, and the concentration of the protein was determined using ImageJ software (National Institutes of Health, Bethesda, MD) with the varied concentration of bovine serum albumin (BSA) as a standard. To a solution of Compound S1 (488 mg, 2.0 mmol) in CH 2 Cl 2 (5 mL), cooled to 0 °C under argon, were added N,N-diisopropylethylamine (0.68 mL, 4.0 mmol) and Fmoc-Cl (517 mg, 2.0 mmol), and the mixture was stirred at room temperature for 20 h. After addition of 1M HCl (aq), the resulting mixture was extracted with CH 2 Cl 2 and the organic layer was washed with H 2 O and brine, dried over MgSO 4 , filtered and concentrated in vacuo to give a crude product, which was purified by recrystallization from toluene-hexane to afford 664 mg (70%) of the title compound as colorless solids. To a solution of Compound S2 (186 mg, 0.40 mmol) in CH 2 Cl 2 (10 mL) was added dropwise trifluoroacetic acid (3.3 mL, 43.4 mmol) and stirred at room temperature for 2 h. The resulting solution was evaporated to give a residue, which was precipitated by adding EtOAc-hexane (1:1) to afford 78 mg (54%) of the title compound as colorless solids. The resulting solids were used to the next reaction without further purification. To a solution of Compound 3 (15 mg, 0.050 mmol) in CH 2 Cl 2 (0.8 mL) were added Compound 2 (22 mg, 0.060 mmol) and N,N-diisopropylethylamine (0.013 mL, 0.075 mmol), and the reaction mixture was stirred at room temperature for 22 h. After addition of H 2 O, the resulting mixture was extracted with CH 2 Cl 2 and the organic layer was washed with brine, dried over MgSO 4 , filtered and concentrated in vacuo to give a crude product, which was purified by silica gel column chromatography (MeOH/ CHCl 3 = 1%) to afford 20 mg (73%) of the title compound as brown oil.
Synthesis of IBA-C8-TAMRA
To a solution of Compound 4 (20 mg, 0.036 mmol) in DMF (0.8 mL) was added piperidine (0.018 ml, 0.18 mmol), and the mixture was stirred at room temperature for 40 min. The resulting solution was evaporated to give a crude product, which was used to next reaction without further purification.
To a solution of Compound 5 (2.8 mg, 9.4 mol) in CH 2 Cl 2 (0.5 mL) was added TAMRA-NHS ester (2.5 mg, 4.7 mol) and stirred at room temperature for 24 h. The resulting solution was evaporated to give a crude product, which was purified by silica gel column chromatography (MeOH/ CHCl 3 = 5%) to afford 2.7 mg (84%) of the title compound as pink solids.
1 H-NMR (CDCl 3 ,400 MHz)  1.20-1.70 (m, 12H), 2.05 (quintet, J = 7 Hz, 2H), 2.23 (t, J = 7 Hz, 2H), 2.80 (t, J = 7 Hz, 2H), 3.00 (s, 12H), 3.24 (q, J = 6 Hz, 2H), 3.48 (q, J = 6 Hz, 2H), 5.47 (brs, 1H), 6.38-6.51 (m, 5H), 6.61 (d, J = 9 Hz, 2H), 6.99 (s, 1H), 7.09 (t, J = 7 Hz, 1H) After incubation at room temperature for 1 hour, the beads were washed three times with 1 mL of Flag wash buffer (20 mM phosphate, 0.5 M NaCl, 60 mM imidazole, 0.1% polyoxyethylene(23)lauryl ether, pH 7.4) on a magnetic rack and incubated with 130 μL of wash buffer that contained 50 μg of Flag peptide at room temperature. After 1 hour, the eluent was collected on a magnet, and applied to 7 k-desalting spin column for changing the buffer to PBST.
TAMRA-conjugated anti-HSA IgG type Q-body was purified using protein G magnetic beads as follows: The sample after UV exposure was subsequently mixed with 490 µL of Tris-buffered saline (TBS: 50 mM Tris, 150 mM NaCl, pH 7.6) and incubated with 50 μL of protein magnetic beads on a rotating wheel at room temperature for 1 hour. The beads were washed three times with 500 uL of TBS on a magnetic rack. After adding 100 μL of 0.1 M glycine, pH 2.0 and incubating at room temperature for 10 min, the eluent was collected on a magnetic rack and neutralized the low pH by adding 15 μL of 1 M Tris, pH 8.5. Subsequently, the sample was applied to 7 k-desalting spin column for changing the buffer to PBST. 
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